Major Depressive Disorder Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis

The Major Depressive Disorder Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Major Depressive Disorder Market?
Recent years have seen consistent growth in the market size for major depressive disorder. The market, valued at $6.12 billion in 2024, is expected to reach $6.28 billion in 2025, reflecting a compound annual growth rate (CAGR) of 2.6%. The growth witnessed in the historic period is credited to advancements in pharmaceuticals, increased awareness surrounding mental health, psychological therapies, and public health initiatives.

The market size for major depressive disorder is anticipated to experience consistent expansion in the coming years. It is projected to reach $7.13 billion by 2029, with a compound annual growth rate (CAGR) of 3.2%. This anticipated growth during the forecast period is linked to factors such as precision medicine, telepsychiatry and teletherapy, innovative treatment methods, and the worldwide extension of mental health services. Key trends within the forecast period comprise of early intervention, peer support and internet-based communities, comprehensive strategies, resilience and coping tactics.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

What Are the Different Major Depressive Disorder Market Segments?
The major depressive disorder market covered in this report is segmented -

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments
2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis
3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:
1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy
2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT
4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)
5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What Are the Primary Drivers Shaping the Major Depressive Disorder Market?
The major depressive disorder market's growth is predicted to be driven by an increase in substance and alcohol abuse cases. These terms refer to patterns of excessive and harmful use of substances, including alcohol, that can result in negative physical, psychological, and social effects. Substance and alcohol abuse often coincide with major depressive disorder, and the two conditions can exacerbate each other, drastically amplifying the risk of physical and mental harm. For example, a survey conducted by the Substance Abuse and Mental Health Services Administration, a department of health and human services based in the US, revealed that 3.1% (or 8.9 million) of the population misused opioids in 2023. Meanwhile, 21.8% of individuals aged 12 or older consumed marijuana, making it the most widely abused illicit drug. Moreover, 9.4% of people aged 12 or older reported vaping nicotine in the past month, marking an increase from 8.3% in 2022. Hence, the escalating cases of substance and alcohol misuse are impelling the growth of the major depressive disorder market. Major Depressive Disorder Market Driver: Surge in Anxiety Cases Propels Market Growth

Which Companies Are Leading in the Major Depressive Disorder Market?
Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

What Are the Major Trends Shaping the Major Depressive Disorder Market?
Leading businesses within the major depressive disorder market strategically aim to design groundbreaking products and secure their approval in order to outperform their competition. The increasing number of approvals for medications for MDD, such as VRAYLAR (cariprazine), reflects the demand for safer and more effective treatments. In December 2022, AbbVie Inc., a pharmaceutical company based in the US, obtained the Food and Drug Administration (FDA) approval for VRAYLAR (cariprazine) to be used as supplementary therapy to antidepressants for treating adult MDD patients. VRAYLAR, an innovative atypical antipsychotic medication, works by optimizing dopamine and serotonin levels in the brain. This drug represents the first atypical antipsychotic to secure approval as a supplementary treatment for MDD. Moreover, VRAYLAR is offered in capsule format intended for daily consumption.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

What Are the Top Revenue-Generating Geographies in the Major Depressive Disorder Market?
North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Major Depressive Disorder Market?
2. What is the CAGR expected in the Major Depressive Disorder Market?
3. What Are the Key Innovations Transforming the Major Depressive Disorder Industry?
4. Which Region Is Leading the Major Depressive Disorder Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.